title: [A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
abstract: The patient was a 36-year-old male. He visited our department in February 2004 as a prior chest X-ray revealed multiple nodular shadows. After further examinations, he was diagnosed with stage IV adenocarcinoma of the lung. As treatment, 5 courses of carboplatin (CBDCA)+docetaxel (DOC), 3 courses of CBDCA+gemcitabine (GEM), 6 weeks of gefitinib, and 3 courses of GEM were administered. However, the tumor progressed, and S-1 (120 mg/day, 2 weeks on, 1 week off) was administered as the sixth regimen from May 2006. No severe side effects were observed, and an antitumor action was achieved over a relatively long period. Therefore, it was suggested that a single administration of S-1 for non-small cell lung cancer, which had been treated with other multiple regimens, is safe, and long-term control of the disease can be expected.
authors.affiliation: Respiratory Medicine, Hirosaki University Graduate School of Medicine.
authors.forename: Koichi
authors.initials: K
authors.lastname: Okudera
authors.forename: Shingo
authors.initials: S
authors.lastname: Takanashi
authors.forename: Akihito
authors.initials: A
authors.lastname: Hayashi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Morimoto
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Nakamura
authors.forename: Megumi
authors.initials: M
authors.lastname: Mikuniya
authors.forename: Junichi
authors.initials: J
authors.lastname: Dempoya
authors.forename: Ken
authors.initials: K
authors.lastname: Okumura
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D004338:Drug Combinations; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004338:Drug Combinations; D011799:Quinazolines; D043823:Taxoids; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid; D016190:Carboplatin; D000077156:Gefitinib; D000093542:Gemcitabine